Pills masthead

Archives: Search / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

2011201020092008200720062004

 
From
To
Aug 30, 2021
Lannett Commences Marketing Mycophenolate Mofetil For Oral Suspension

Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL, an internally developed product. Total U.S. sales of...

More
Aug 25, 2021
Lannett Announces Fiscal 2021 Fourth-Quarter, Full-Year Financial Results

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2021 fourth quarter and full year ended June 30, 2021. "With the recently signed agreement to be the exclusive...

More
Aug 18, 2021
Lannett To Report Fiscal 2021 Fourth-quarter, Full-year Financial Results, Host Conference Call On Wednesday, August 25

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2021 fourth quarter and full year on Wednesday, August 25, 2021, after the market closes....

More
Jul 29, 2021
LANNETT expands respiratory pipeline, signs exclusive distribution agreement for generic SPIRIVA® handihaler®

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive U.S. commercialization agreement for a therapeutically equivalent generic of Spiriva® Handihaler®...

More
Jul 12, 2021
Lannett Launches Fluvastatin Sodium ER Tablets

Lannett Company, Inc. (NYSE: LCI) today announced that it recently began marketing Fluvastatin Sodium Extended-release Tablets, 80 mg, a partnered product. Total U.S. sales of Fluvastatin Sodium...

More
Jun 1, 2021
Lannett Announces FDA Acceptance, As A Priority Original ANDA, Of The Generic Advair Diskus® Filing

Lannett Company, Inc. (NYSE: LCI) today announced the U.S. Food and Drug Administration (FDA) has accepted the Abbreviated New Drug Application (ANDA) for Fluticasone Propionate and Salmeterol...

More
May 5, 2021
Lannett Announces Fiscal 2021 Third-Quarter Financial Results

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2021 third quarter ended March 31, 2021. "In recent months, we have significantly advanced a number of strategic...

More
Apr 28, 2021
Lannett To Report Fiscal 2021 Third-Quarter Financial Results, Host Conference Call On Wednesday, May 5

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2021 third quarter on Wednesday, May 5, 2021, after the market closes. Lannett management...

More
Apr 22, 2021
Lannett Announces Closing Of $350 Million Senior Secured Notes And $190 Million Second Lien Senior Secured Loan Facility

Lannett Company, Inc. (NYSE: LCI) today announced the closing of the $350 million aggregate principal amount of 7.750% senior secured notes due 2026 (the "Notes") in a private placement to...

More
Apr 9, 2021
Lannett Announces Pricing Of $350 Million Senior Secured Notes Due 2026

Lannett Company, Inc. (NYSE: LCI) (the "Company" or "Lannett") today announced the pricing of the $350 million aggregate principal amount of 7.75% senior secured notes due 2026 (the "Notes") in a...

More
Apr 6, 2021
Lannett Announces Offering Of $350 Million Senior Secured Notes Due 2026

Lannett Company, Inc. (NYSE: LCI) (the "Company") today announced that it intends to offer, subject to market conditions and other factors, $350 million aggregate principal amount of senior...

More
Apr 1, 2021
Lannett Submits ANDA For Generic ADVAIR DISKUS®

Lannett Company, Inc. (NYSE: LCI) today announced the submission of an Abbreviated New Drug Application (ANDA) for Fluticasone propionate and Salmeterol inhalation powder (100/50 mcg, 250/50 mcg...

More
Mar 10, 2021
Lannett Development Of Biosimilar Insulin Glargine Product Continues To Advance

Lannett Company, Inc. (NYSE: LCI) today announced that it recently received feedback from the U.S. Food and Drug Administration (FDA) regarding biosimilar insulin glargine, a product the company...

More
Feb 9, 2021
Lannett Expands Strategic Relationship To Include Biosimilar Fast-Acting Insulin

Lannett Company, Inc. (NYSE: LCI) today announced that it has added a new co-development agreement for biosimilar insulin aspart with its strategic alliance partners within the HEC Group of...

More
Feb 8, 2021
Lannett Begins Marketing Chlorpromazine Hydrochloride Tablets

Lannett Company, Inc. (NYSE: LCI) today announced that it has begun marketing Chlorpromazine Hydrochloride Tablets, USP, 10 mg, 25 mg, 50 mg, 100 mg and 200 mg. The company recently received...

More
Feb 3, 2021
Lannett Announces Fiscal 2021 Second-Quarter Financial Results In Line Or Above Expectations

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2021 second quarter ended December 31, 2020. "For the fiscal 2021 second quarter, net sales exceeded our...

More
Jan 27, 2021
Lannett To Report Fiscal 2021 Second-Quarter Financial Results, Host Conference Call On Wednesday, February 3

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2021 second quarter on Wednesday, February 3, 2021, after the market closes. Lannett...

More
Dec 7, 2020
Lannett Announces New $30 Million Revolving Credit Facility

Lannett Company, Inc. (NYSE: LCI) today announced the closing of a $30 million asset-backed revolving credit facility with Wells Fargo Bank, National Association. "Completing this transaction...

More
Nov 30, 2020
Lannett Pays Off, In Full, Remaining Term A Loans

Lannett Company, Inc. (NYSE: LCI) today announced that the company used a portion of its existing cash on hand to pay off, in full, the remaining $42 million outstanding balance of its Term A...

More
Nov 4, 2020
Lannett Announces Fiscal 2021 First-quarter Financial Results; Affirms Guidance

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2021 first quarter ended September 30, 2020. "We view our fiscal 2021 first quarter net sales of $126 million as a...

More
Nov 3, 2020
Lannett Launches Authorized Generic of Tirosint® (Levothyroxine Sodium Capsules)

Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced the launch of the authorized generic of Tirosint® (Levothyroxine Sodium Capsules USP). Lannett entered into an exclusive...

More
Oct 28, 2020
Lannett To Report Fiscal 2021 First-Quarter Financial Results, Host Conference Call On Wednesday, November 4

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2021 first quarter on Wednesday, November 4, 2020, after the market closes. Lannett...

More
Aug 26, 2020
Lannett Announces Fiscal 2020 Fourth-Quarter, Full-Year Financial Results

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2020 fourth quarter and full year ended June 30, 2020. "For both the fiscal 2020 full year and fourth quarter, our...

More
Aug 19, 2020
Lannett To Report Fiscal 2020 Fourth-Quarter, Full-Year Financial Results, Host Conference Call On Wednesday, August 26

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2020 fourth quarter and full year on Wednesday, August 26, 2020, after the market closes....

More
Aug 17, 2020
Lannett Announces Notice Of Proposed Settlement And Dismissal With Prejudice Of Derivative Action

Lannett Company, Inc. (NYSE: LCI) today announced the Notice of Proposed Settlement and Dismissal with Prejudice of Derivative Action (the "Notice"), a copy of which is attached hereto as an...

More
1-25      26-50      51-75      76-100      101-125      126-150      151-175      176-200      201-225      226-250      251-275      276-300      301-325      326-350      351-375      376-400      401-425      426-450      451-475      476-500      501-525      526-550      551-575      576-600      601-625      626-650      651-675      676-679
Price Data
NYSELCI